THNR

Amplify Weight Loss Drug & Treatment ETF

THNR

Market cap $4.16M

Overview Fund Activity

23.09 USD

-0.09

0.39%

At close Updated Sep 15, 2:50 PM EDT

1 day

-0.39%

5 days

-0.35%

1 month

0.65%

3 months

-1.54%

6 months

1.45%

Year to date

2.03%

1 year

-16.64%

5 years

-9.09%

10 years

-9.09%

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

29.52% less ownership

Funds ownership: 35.86% [Q1] → 6.34% (-29.52%) [Q2]

50% less funds holding

Funds holding: 4 [Q1] → 2 (-2) [Q2]

87% less capital invested

Capital invested by funds: $1.39M [Q1] → $187K (-$1.2M) [Q2]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

See Fund Rankings

Financial journalist opinion

Zacks Investment Research

Weight Loss Drug ETF (THNR) Hits New 52-Week High

Amplify Weight Loss Drug & Treatment ETF THNR is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 51.9% from its 52-week low price of $18.56/share.

Weight Loss Drug ETF (THNR) Hits New 52-Week High

New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs

For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to consider the investment opportunity in weight loss as a theme.

New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs

Disruptive Theme of the Week: 2024's Top Investment Themes & Trends

2024 was an amazing year for investment performance, with the broad market S&P 500 TR Index up over 28%. There were also some serious ETF milestones achieved this year.

Disruptive Theme of the Week: 2024's Top Investment Themes & Trends

Disruptive Theme of the Week – Breakthroughs in Medicine

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.

Disruptive Theme of the Week – Breakthroughs in Medicine

Disruptive Theme of the Week: Happy Post-Election Themes

With the completion of a close presidential election, roughly half of us are likely disappointed regardless of the winner. To counter the post-election blues, I identified some “happy” ETF themes to consider for investment.

Disruptive Theme of the Week: Happy Post-Election Themes

Amplify ETFs Hits $10 Billion in Assets Amid New ETF Launches

As the ETF landscape continues to expand, more and more firms are crossing over significant AUM thresholds. That includes some now-veteran shops with strong, growing rosters, like Amplify ETFs.

Amplify ETFs Hits $10 Billion in Assets Amid New ETF Launches

Zacks Investment Research

Tap the Weight-Loss Drug Market With These ETFs

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

Tap the Weight-Loss Drug Market With These ETFs

Disruptive Theme of the Week: Playing Defense

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

Zacks Investment Research

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

SILJ, HACK, THNR: Trends in Thematic Investing

Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.

See News Rankings

Charts implemented using Lightweight Charts™